Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Cerilliant
Fish and Richardson
Chinese Patent Office
McKesson
US Army
Medtronic
Merck
Cantor Fitzgerald
Dow

Generated: August 21, 2017

DrugPatentWatch Database Preview

ZOLINZA Drug Profile

« Back to Dashboard

Which patents cover Zolinza, and what generic Zolinza alternatives are available?

Zolinza is a drug marketed by Merck and is included in one NDA. There are nine patents protecting this drug.

This drug has one hundred and twenty-eight patent family members in thirty-five countries.

The generic ingredient in ZOLINZA is vorinostat. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vorinostat profile page.

Summary for Tradename: ZOLINZA

Patents:9
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list76
Clinical Trials: see list142
Patent Applications: see list4,355
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZOLINZA at DailyMed

Pharmacology for Tradename: ZOLINZA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RXYesYes► Subscribe► Subscribe ► Subscribe
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZOLINZA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006► Subscribe► Subscribe
Merck
ZOLINZA
vorinostat
CAPSULE;ORAL021991-001Oct 6, 2006► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZOLINZA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,148,257Methods of treating mesothelioma with suberoylanilide hydroxamic acid► Subscribe
8,288,440Formulations of suberoylanilide hydroxamic acid and methods for producing same► Subscribe
7,847,122Polymorphs of suberoylanilide hydroxamic acid► Subscribe
7,375,137Methods of treating cancer with HDAC inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ZOLINZA

Country Document Number Estimated Expiration
CroatiaP20060080► Subscribe
Japan5264174► Subscribe
Australia2008246251► Subscribe
TaiwanI365068► Subscribe
EcuadorSP066452► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Argus Health
Daiichi Sankyo
Federal Trade Commission
Cantor Fitzgerald
Johnson and Johnson
Cipla
Chinese Patent Office
Covington
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot